Combined clinical trial results of a HER2/neu (E75) vaccine for the prevention of recurrence in high-risk breast cancer patients: U.S. Military Cancer Institute Clinical Trials Group study I-01 and I-02

Clinical Cancer Research

Volumn 14, Issue 3, 2008, Pages 797-803

  Peoples, George E ^a,b   Holmes, Jarrod P ^b,c   Hueman, Matthew T ^b,c   Mittendorf, Elizabeth A ^d   Amin, Asna ^b,c   Khoo, Steven ^b,c   Dehqanzada, Zia A ^b,c   Gurney, Jennifer M ^b   Woll, Michael M ^b   Ryan, Gayle B ^b   Storrer, Catherine E ^b   Craig, Dianna ^e   Ioannides, Constantin G ^d   Ponniah, Sathibalan ^b  

^a BROOKE ARMY MEDICAL CENTER   (United States)

^b UNIFORMED SERVICES UNIVERSITY OF THE HEALTH SCIENCES   (United States)

^c WALTER REED ARMY MEDICAL CENTER   (United States)

^d UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^e Windber Medical Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER VACCINE; CANCER VACCINE E75; EPIDERMAL GROWTH FACTOR RECEPTOR 2; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HLA A2 ANTIGEN; HLA A3 ANTIGEN; TRASTUZUMAB; UNCLASSIFIED DRUG;

ADULT; AGED; ANGIONEUROTIC EDEMA; ARTICLE; BONE PAIN; BREAST CANCER; CANCER IMMUNOTHERAPY; CANCER RECURRENCE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DELAYED HYPERSENSITIVITY; DOSE RESPONSE; DRUG DOSE ESCALATION; DRUG SAFETY; ERYTHEMA; FATIGUE; FEMALE; FLU LIKE SYNDROME; FOLLOW UP; GENE OVEREXPRESSION; HIGH RISK PATIENT; HUMAN; IN VITRO STUDY; IN VIVO STUDY; INJECTION SITE ERYTHEMA; INJECTION SITE INDURATION; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; RECURRENCE RISK; STATISTICAL SIGNIFICANCE; VACCINE PRODUCTION;

ANNEXIN A5; BREAST NEOPLASMS; CANCER VACCINES; CELL DIVISION; CELL LINE, TUMOR; DNA PRIMERS; FEMALE; HLA-A2 ANTIGEN; HLA-A3 ANTIGEN; HUMANS; MILITARY MEDICINE; RECEPTOR, ERBB-2; RECURRENCE; SAFETY; UNITED STATES;

EID: 38949139497     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-07-1448     Document Type: Article

References (34)

1. Slamon DJ, Godolphin W, Jones LA, et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science1989;244:707-12.
2. Pritchard KI, Shepherd LE, O'Malley FP, et al. HER2 and responsiveness of breast cancer to adjuvant chemotherapy. N Engl J Med 2006;354:2103-11.
3. Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001;344:783-92.
4. Piccart-Gebhart MJ, Procter M, Leyland-Jones B, et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 2005;353:1659-72.
5. Romond EH, Perez EA, Bryant J, et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 2005;353:1673-84.
6. Joensuu H, Kellokumpu-Lehtinen PL, Bono P, et al. Adjuvant docetaxol or vinorelbine with or without trastuzumab for breast cancer. N Engl J Med 2006;354:809-20.
7. Emens LA, Reilly RT, Jaffee EM. Breast cancer vaccines: maximizing cancer treatment by tapping into host immunity. Endocr Relat Cancer 2005;12:1-17.
8. Peoples GE, Goedegburre PS, Smith R, et al. Breast and ovarian cancer-specific cytotoxic T lymphocytes recognize the same HER2/neu-derived peptide. Proc Natl Acad Sci U S A 1995;92:432-6.
9. Fisk B, Blevins TL, Wharton JT, Ioannides CG. Identification of an immunodominant peptide of HER-2/neu protooncogene recognized by ovarian tumor-specific cytotoxic T lymphocyte lines. J Exp Med 1995;181:2109-17.
10. Zaks TZ, Rosenberg SA. Immunization with a peptide epitope (p369-377) from HER-2/neu leads to peptide-specific cytotoxic T lymphocytes that fail to recognize HER-2/neu+ tumors. Cancer Res 1998;58:4902-8.
11. Knutson KL, Schiffman K, Cheever MA, Disis ML. Immunization of cancer patients with a HER-2/neu, HLA-A2 peptide, p369-377, results in short-lived peptide-specific immunity. Clin Cancer Res 2002;8:1014-8.
12. Murray JL, Gillogly ME, Przepiorka D, et al. Toxicity, immunogenicity, and induction of E75-specific tumor-lytic CTLs by HER-2 peptide E75 (369-377) combined with granulocyte macrophage colony-stimulating factor in HLA-A2+ patients with metastatic breast and ovarian cancer. Clin Cancer Res 2002;8:3407-18.
13. Brossart P, Wirths S, Stuhler G, Reichardt VL, Kanz L, Brugger W. Induction of cytotoxic T-lymphocyte responses in vivo after vaccinations with peptide-pulsed dendritic cells. Blood 2000;96:3102-8.
14. Kono K, Takahashi A , Sugai H, et al. Dendritic cells pulsed with HER-2/neu-derived peptides can induce specific T-cell responses in patients with gastric cancer. Clin Cancer Res 2002;8:3394-400.
15. Disis ML, Grabstein KH, Sleath PR, Cheever MA. Generation of immunity to the HER-2/neu oncogenic protein in patients with breast and ovarian cancer using a peptide-based vaccine. Clin Cancer Res 1999;5:1289-97.
16. Disis ML, Gooley TA, Rinn K, et al. Generation of T-cell immunity to the HER-2/neu protein after active immunization with HER-2/neu peptide-based vaccines. J Clin Oncol 2002;20:2624-32.
17. Parmiani G, Castelli C, Pilla L, Santinami M, Colombo MP, Rivoltini L. Opposite immune functions of GM-CSF administered as vaccine adjuvant in cancer patients. Ann Oncol 2007;18:226-32.
18. Schaed SG, Klimek VM, Panageas KS, et al. T-cell responses against tyrosinase 368-376(370D) peptide in HLA* A0201 + melanoma patients: randomized trial comparing incomplete Freund's adjuvant, granulocyte macrophage colony-stimulating factor, and QS-21 as immunological adjuvants. Clin Cancer Res 2002;8:967-72.
19. Hueman MT, Dehqanzada ZA , Novak TE, et al. Phase I of a HER-2/neu peptide (E75) for the prevention of prostate-specific antigen recurrence in high-risk prostate cancer patients. Clin Cancer Res 2005;11:7470-9.
20. Peoples GE, Gurney JM, Hueman MT, et al. Clinical trial results of a HER2/neu (E75) vaccine to prevent recurrence in high-risk breast cancer patients. J Clin Oncol 2005;23:7536-45.
21. LeeTD. Distribution of HLA antigens in North American Caucasians, North American Blacks and Orientals. In: Lee J, editor: The HLAS ystem. NewYork: Springer-Verlag; 1990. p.141.
22. Parker KC, Bednarek MA, Coligan JE. Scheme for ranking potential HLA-A2 binding peptides based on independent binding of individual peptide side-chains. J Immunol 1994;152:163-75.
23. Rammensee HG, Bachmann J, Stevanovic S. MHC Ligands and Peptide Motifs. NewYork; 1997.
24. Woll MM, Fisher CM, Ryan GB, et al. Direct measurement of peptide-specific CD8+ T cells using HLA-A2:Ig dimer for monitoring the in vivo immune response to a HER2/neu vaccine in breast and prostate cancer patients. J Clin Immunol 2004;24:449-61.
25. Sokal JE. Measurement of delayed skin-test responses. N Engl J Med 1975;293:501-2.
26. Park BK, Zhang H, Zeng Q, et al. NF-κB in breast cancer cells promotes osteolytic bone metastases by inducing osteoclastogenesis via GM-CSF. Nat Med 2007;13:62-9.
27. Disis ML, Schiffman K, Gooley TA, McNeel DG, Rinn K, Knutson KL. Delayed-type hypersensitivity response is a predictor of peripheral blood T-cell immunity after HER-2/neu peptide immunization. Clin Cancer Res 2000;6:1347-50.
28. Hoos A, Parmiani G, Hege K, et al. A clinical development paradigm for cancer vaccines and related biologics. J Immunother 2007;30:1-15.
29. Stojadinovic S, Hueman MT, Holmes JP, Hueman MT, Ponniah S, Peoples GE. Quantification and phenotypic characterization of circulating tumor cells (CTCs) for monitoring response to preventative vaccine-based immunotherapy for breast cancer. Ann Surg Oncol 2007;S14:26.
30. Gamzatova Z, Villabona L, Dahlgren L, et al. Human leucocyte antigen (HLA) A2 as a negative clinical prognostic factor in patients with advanced ovarian cancer. Gynecol Oncol 2006;103:145-50.
31. De Petris L, Bergfeldt K, Hising C, et al. Correlation between HLA-A2 gene frequency, latitude, ovarian and prostate cancer mortality rates. Med Oncol 2004;21:49-52.
32. Patanaphan V, Salazar OM, Risco R. Breast cancer: metastatic patterns and their prognosis. South Med J 1988;81:1109-12.
33. Sherry MM, Greco FA, Johnson DH, Hainsworth JD. Breast cancer with skeletal metastases at initial diagnosis: distinctive clinical characteristics and favorable prognosis. Cancer 1986;58:178-82.
34. Perez JE, Machiavelli M, Leone BA, et al. Bone-only versus visceral-only metastatic pattern in breast cancer: analysis of 150 patients. A GOCS study. Grupo Oncologico Cooperativo del Sur. Am J Clin Oncol 1990;13:294-8.